| Investigator |
NCT05106751: A Randomized, Multicenter, Evaluator-Blinded, Active-Controlled, Parallel-Group Investigation to Evaluate the Performance and Safety of YVOIRE® Classic Plus Versus Comparator for Temporary Correction of Nasolabial Folds |
|
|
| Completed | 4 | 104 | Europe | Hyaluronic acid dermal filler | LG Chem | Correction of Nasolabial Folds | 09/22 | 04/23 | | |
OPERA-T, NCT05238116 / 2021-004554-32: Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis ( Study) |
|
|
| Recruiting | 3 | 123 | Europe, Canada, US, RoW | PC945, Placebo | Pulmocide Ltd | Refractory IPA | 03/26 | 04/26 | | |
| Active, not recruiting | 3 | 94 | Europe, US, RoW | Hydroxypropyl-beta-cyclodextrin, Trappsol Cyclo, Placebo, 0.5N saline | Cyclo Therapeutics, Inc. | Niemann-Pick Disease, Type C1 | 06/25 | 06/26 | | |
| Completed | 3 | 530 | Europe, RoW | Cefepime-zidebactam (FEP-ZID), Meropenem | Wockhardt, Medpace, Inc. | Complicated Urinary Tract Infection, Acute Pyelonephritis | 01/25 | 01/25 | | |
Integral-1, NCT05887908 / 2021-001441-12: Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis |
|
|
| Completed | 3 | 614 | Europe | co-administration of cefepime and nacubactam, co-administration of aztreonam and nacubactam, imipenem/cilastatin | Meiji Seika Pharma Co., Ltd., Japan Agency for Medical Research and Development | Complicated Urinary Tract Infection, Acute Pyelonephritis | 11/24 | 11/24 | | |
Integral-2, NCT05905055 / 2021-001396-16: P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales |
|
|
| Recruiting | 3 | 150 | Japan | co-administration of cefepime and nacubactam, co-administration of aztreonam and nacubactam, BAT | Meiji Seika Pharma Co., Ltd., Japan Agency for Medical Research and Development | Complicated Urinary Tract Infection, Acute Pyelonephritis, Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, Complicated Intra-abdominal Infection | 02/25 | 02/25 | | |
| Recruiting | 2 | 90 | US | Hydroxypropyl Beta Cyclodextrin, Trappsol Cyclo, Placebo, 0.5N saline | Cyclo Therapeutics, Inc., Cyclo Therapeutics Inc. | Alzheimer's Disease | 03/24 | 03/24 | | |
NCT06564311: A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone) |
|
|
| Recruiting | 2 | 93 | Europe, US, RoW | Obexelimab, Placebo | Zenas BioPharma (USA), LLC | Relapsing Multiple Sclerosis | 08/25 | 02/26 | | |
NCT05113342: Descartes-25 in Relapsed/Refractory Multiple Myeloma |
|
|
| Terminated | 1 | 9 | US, RoW | Descartes-25, DC-25 | Cartesian Therapeutics | Multiple Myeloma, Relapse Multiple Myeloma | 05/23 | 11/24 | | |
SER-155-001, NCT04995653: A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT |
|
|
| Completed | 1 | 60 | US | Vancomycin Pre-Treatment, Vancomycin Placebo, SER-155, SER-155 Placebo | Seres Therapeutics, Inc., Memorial Sloan Kettering Cancer Center | Allogeneic Hematopoietic Stem Cell Transplantation | 07/24 | 07/24 | | |
NCT04784299: To Evaluate the Performance and Safety of YVOIRE Volume Plus for Improvement of Mid-face Volume |
|
|
| Completed | N/A | 105 | Europe | YVOIRE volume plus, Restylane Lyft with Lidocaine | LG Chem | Midface Volume Deficit | 04/22 | 10/22 | | |
NCT05314504: Clinical Investigation of YVOIRE Y-Solution 360 for Lip Augmentation in China |
|
|
| Completed | N/A | 174 | RoW | YVOIRE Y-Solution 360 | LG Chem | Lip Augmentation | 02/23 | 02/24 | | |
| Active, not recruiting | N/A | 139 | Europe | Remote monitoring, patientMpower app | Imperial College Healthcare NHS Trust, patientMpower Ltd., Imperial College London, University College, London, Action for Pulmonary Fibrosis | Interstitial Lung Disease | 03/25 | 04/25 | | |
